SCHEMBL24252448

SCHEMBL24252448

OC12CCCC1(O)CCC2

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3397459 1.00 ALDH1A1 (0.30) ALDH1A1
SCHEMBL458674 0.95
SCHEMBL7913334 0.95 ALDH1A1 (0.35) ALDH1A1
SCHEMBL18249750 0.91 ALDH1A1 (0.40) ALDH1A1
SCHEMBL4612532 0.90 ALDH1A1 (0.37) ALDH1A1
SCHEMBL641966 0.90 ALDH1A1 (0.37) ALDH1A1
SCHEMBL1539174 0.90 ALDH1A1 (0.37) ALDH1A1
SCHEMBL6048331 0.86 ALDH1A1 (0.42) ALDH1A1
SCHEMBL11423768 0.86 ALDH1A1 (0.42) ALDH1A1
SCHEMBL3708709 0.86 ALDH1A1 (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 ALDH1A1 653/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 ALDH1A1 653/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 ALDH1A1 653/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH ALDH1A1 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.